NexGard

Active Ingredient:: Afoxolaner
Brand:: NexGard
Origin:: European Union

NexGard (Afoxolaner)

Afoxolaner, the active ingredient in NexGard, is a isoxazoline presented as a chewable tablet for oral use. It treats flea and tick infestations in dogs by delivering systemic ectoparasite control through a single monthly dose, offering convenient and rapid protection.

GNH India supplies NexGard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for veterinary professionals seeking high‑quality antiparasitic solutions, ensuring compliance with regulatory standards and timely delivery across global markets for all customers.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

NexGard (afoxolaner) is an isoxazoline ectoparasiticide used to control external parasites in dogs.
Flea infestation: eliminates adult fleas and prevents new infestations for up to one month.
Tick infestation: kills attached ticks and prevents attachment of new ticks for up to one month.
Canine ectoparasite control: provides broad‑spectrum protection against common external parasites in dogs.

How It Works

Afoxolaner acts by selectively inhibiting ligand‑gated GABA‑chloride channels in the nervous system of fleas and ticks. This blockade leads to uncontrolled neuronal activity, hyperexcitation, paralysis, and death of the parasites, while mammalian GABA receptors are less affected, allowing safe systemic exposure in the host.

Side Effects

Adverse reactions reported with NexGard are generally mild, but veterinary monitoring is advised.

Common Side Effects

Mild gastrointestinal upset: occasional vomiting or soft stools.
Transient lethargy: temporary reduced activity.
Reduced appetite: brief decrease in food intake.

Serious or Rare Side Effects

Seizures: rare neurologic events.
Anaphylactic reactions: severe allergic response.
Severe dermatitis: intense skin inflammation.

Precautions & Warnings

When using NexGard, consider the following precautions:

Dosage determination: based on the dog's weight as prescribed by a veterinarian.
Age restriction: not recommended for puppies under 8 weeks or under 2 kg.
Concurrent medications: review potential interactions with other ectoparasitic products.
Health status: use with caution in dogs with known neurological disorders.
Pregnancy and lactation: safety not established; consult veterinarian.
Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Potential drug interactions with NexGard should be evaluated by a veterinarian.

Major Interactions (Avoid)

Co‑administration with other isoxazoline products: risk of additive neurotoxicity.
Concurrent use of strong CYP3A4 inhibitors: may increase afoxolaner exposure.
Use with phenobarbital: potential antagonism.

Moderate Interactions (Monitor Closely)

Combination with other flea/tick preventatives: monitor for additive side effects.
Concurrent use of certain antihistamines: may increase sedation.

Frequently Asked Questions

NexGard is a veterinary medication indicated for the treatment and prevention of flea and tick infestations in dogs. It provides systemic ectoparasite control when administered orally as a chewable tablet, helping to protect dogs from common external parasites.

Afoxolaner, the active ingredient in NexGard, selectively blocks GABA‑gated chloride channels in fleas and ticks. This inhibition causes uncontrolled neuronal firing, leading to paralysis and death of the parasites while sparing the host animal.

The dose of NexGard is determined by the prescribing veterinarian based on the individual dog's body weight. The product is supplied in chewable tablets calibrated for specific weight ranges, and the exact dosing schedule is set by the animal health professional.

Safety data for NexGard in pregnant or lactating dogs are limited. Veterinarians are advised to weigh the potential benefits against any unknown risks before prescribing it to breeding, pregnant, or nursing animals.

To order NexGard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

NexGard belongs to the isoxazoline class, similar to fluralaner and sarolaner. Compared with older spot‑on or collar products, isoxazolines like NexGard offer a convenient oral monthly dose, rapid systemic action, and broad‑spectrum efficacy against both fleas and ticks.

NexGard chewable tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children and other animals.

NexGard is given orally as a chewable tablet. The tablet can be offered directly to the dog to chew or can be concealed in food. Administration is typically once a month, as directed by the veterinarian.

Serious adverse events, although rare, include seizures, severe allergic reactions such as anaphylaxis, and intense skin inflammation (dermatitis). Owners should seek immediate veterinary attention if any of these symptoms appear after treatment.

NexGard should not be used in dogs younger than 8 weeks of age, weighing less than 2 kg, or in animals with a known hypersensitivity to afoxolaner or any component of the formulation. Caution is also advised for dogs with pre‑existing neurological disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

NexGard (Afoxolaner)

Indications & Clinical Uses

How It Works